drugset / Trial / NCT00081263
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
RandomizedParallel-groupDouble-blindPrevention
Summary
This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia.
Timeline
- Start
- 2005-06
- Primary completion
- 2012-09
- Completion
- —
Outcome
Missed primary endpoint
paper In primary analysis, histologic regression was not significantly higher in the celecoxib group (40%) than in the placebo group (34.1%). PMID 28285845 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |